Cargando…
Treatment of Chronic HCV Infection in Special Populations
The mainstay of treatment of chronic hepatitis C is pegylated interferon combined with ribavirin and more than 50% of naïve patients will have viral cure with either 6 months (genotypes 2 and 3) or 12 months (genotypes 1,4, and 6) with the initial treatment. However, populations have been defined th...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1415846/ https://www.ncbi.nlm.nih.gov/pubmed/16614746 |
_version_ | 1782127131057192960 |
---|---|
author | Hoefs, John Aulakh, Vikramjit S. |
author_facet | Hoefs, John Aulakh, Vikramjit S. |
author_sort | Hoefs, John |
collection | PubMed |
description | The mainstay of treatment of chronic hepatitis C is pegylated interferon combined with ribavirin and more than 50% of naïve patients will have viral cure with either 6 months (genotypes 2 and 3) or 12 months (genotypes 1,4, and 6) with the initial treatment. However, populations have been defined that respond less well to routine treatment including African Americans, immune suppressed populations, obese patients and cirrhotic patients. These types of patients are enriched in groups of patients who are non-responders to treatment. This article discusses viral kinetics that may impact treatment response, strategies to maximize treatment effectiveness in these populations and the treatment of non-responders in general. Early viral kinetics can be used to define response or non-response and these results can be used to modify subsequent treatment length and dose. |
format | Text |
id | pubmed-1415846 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-14158462006-04-13 Treatment of Chronic HCV Infection in Special Populations Hoefs, John Aulakh, Vikramjit S. Int J Med Sci Review The mainstay of treatment of chronic hepatitis C is pegylated interferon combined with ribavirin and more than 50% of naïve patients will have viral cure with either 6 months (genotypes 2 and 3) or 12 months (genotypes 1,4, and 6) with the initial treatment. However, populations have been defined that respond less well to routine treatment including African Americans, immune suppressed populations, obese patients and cirrhotic patients. These types of patients are enriched in groups of patients who are non-responders to treatment. This article discusses viral kinetics that may impact treatment response, strategies to maximize treatment effectiveness in these populations and the treatment of non-responders in general. Early viral kinetics can be used to define response or non-response and these results can be used to modify subsequent treatment length and dose. Ivyspring International Publisher 2006-04-01 /pmc/articles/PMC1415846/ /pubmed/16614746 Text en © Ivyspring International Publisher. This is an open access article. Reproduction is permitted for personal and noncommerical use, provided that the article is in whole, unmodified, and properly cited. |
spellingShingle | Review Hoefs, John Aulakh, Vikramjit S. Treatment of Chronic HCV Infection in Special Populations |
title | Treatment of Chronic HCV Infection in Special Populations |
title_full | Treatment of Chronic HCV Infection in Special Populations |
title_fullStr | Treatment of Chronic HCV Infection in Special Populations |
title_full_unstemmed | Treatment of Chronic HCV Infection in Special Populations |
title_short | Treatment of Chronic HCV Infection in Special Populations |
title_sort | treatment of chronic hcv infection in special populations |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1415846/ https://www.ncbi.nlm.nih.gov/pubmed/16614746 |
work_keys_str_mv | AT hoefsjohn treatmentofchronichcvinfectioninspecialpopulations AT aulakhvikramjits treatmentofchronichcvinfectioninspecialpopulations |